Enhancing Capital’s Bristol-Myers Squibb BMY Stock Holding History

Enhancing Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.33M	Hold	37,300	–	–	1.61%	19
2026 Q2	$2.15M	Hold	37,300	–	–	1.48%	22
2026 Q1	$2.26M	Hold	37,300	–	–	1.68%	20
2025 Q4	$2.01M	Hold	37,300	–	–	1.44%	21
2025 Q3	$1.68M	Hold	37,300	–	–	1.23%	27
2025 Q2	$1.73M	Hold	37,300	–	–	1.32%	25
2025 Q1	$2.27M	Hold	37,300	–	–	1.82%	16
2024 Q4	$2.11M	Buy	+37,300	New	+$2.08M	1.68%	19
2022 Q3	$2.6M	Hold	37,300	–	–	3.22%	6
2022 Q2	$2.87M	Hold	37,300	–	–	3.43%	6
2022 Q1	$2.72M	Hold	37,300	–	–	2.91%	7
2021 Q4	$2.33M	Buy	+37,300	New	+$2.19M	2.53%	11

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Enhancing Capital's BMY Position: Q3 2026 in Review

Enhancing Capital held its Bristol-Myers Squibb (BMY) position steady in Q3 2026 at 37,300 shares worth $2.33M. The position accounts for 1.61% of the portfolio, ranked #19.

Enhancing Capital first reported a position in BMY in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.87M in Q2 2022. 1,030 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

Enhancing Capital held 37,300 shares of Bristol-Myers Squibb worth $2.33M as of Q3 2026.
Enhancing Capital left its Bristol-Myers Squibb share count unchanged in Q3 2026.
Bristol-Myers Squibb made up 1.61% of Enhancing Capital's portfolio in Q3 2026, its #19 holding.
Enhancing Capital first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 12 quarters since.
Enhancing Capital's Bristol-Myers Squibb position peaked at $2.87M in Q2 2022.
1,030 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Enhancing Capital's 13F filing for Q3 2026, filed 26 Oct 2026.